The United Kingdom's National Institute for Health Research (NIHR), part of the National Health Service (NHS), has created a website to educate the public about biosimilar drugs.
The United Kingdom's National Institute for Health Research (NIHR), part of the National Health Service (NHS), has created a website to educate the public about biosimilar drugs. The website, Focus on Biosimilars, explains the background of biologic drugs and the subsequent development of biosimilar drugs, which the NHS says, “may well hold the key to ensuring the sustainability of our globally renowned public healthcare system” because biosimilars can broaden access to expensive biologic treatments that would otherwise be denied to some patients.
Focus on Biosimilars is divided into 3 portals, one each for pharmaceutical companies, NHS healthcare professionals, and NHS patients and caregivers. The patient portal features interviews with patients, nurses, clinicians and pharmacists. These videos help to explain typical patient experiences with biosimilars, what switching programs are, how patients can benefit from clinical trials of biosimilars, as well as the definition of biosimilars and how they differ from originator biologics.
The 3 portals of Focus on Biosimilars explore many key questions associated with biosimilars in use by the NHS, including:
The website points out that uptake and acceptance of biosimilars has rapidly accelerated across the NHS in recent years. The site discusses the problem that lies with “The Usual Suspects” scenario, in which it is difficult to find clinicians interested in conducting clinical trials of biosimilars when “the usual contacts” among key medical research areas are not interested in participating in biosimilar trials. The NHS addressed this issue by having the NIHR Clinical Research Network (CRN) create biosimilar clinical trial packages that offer an alternative route to finding appropriate biosimilar study investigators and sites across the region.
The website also provides links to related information, including updates from the FDA and other international regulatory organizations, advice about local adoption of biosimilars, patient organizations and foundations, and links to information about how to participate in UK clinical trials of biosimilars.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.